Cardiology

ESC Congress 2025: Innovations, AI, and Patient-Centric Care in Cardiology

At this year’s European Society of Cardiology (ESC) Congress in Madrid, one of the world’s largest medical conferences, I was privileged to see how cardiology is evolving and how AI in cardiology and digital health are not just buzzwords but real drivers toward more equitable, effective, and patient-centric care. The sessions offered hope, especially for…...
Read More

Top Stories

Nelson memo

The Nelson Memo: Igniting a Global Open Data

The landscape of scientific research is undergoing a seismic...
Rare diseases

Rare Diseases – An Evolving Medical

A disease is considered rare when it affects fewer than 1 in...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
World patient safety day 2025

World Patient Safety Day 2025: Every Child Deserves Safe Care From Their Very First Breath

Today, September 17, 2025, marks World Patient Safety Day 2025, a global initiative that highlights...
Patient Centricity

The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality

Patient centricity: A defining imperative in healthcare As patient expectations evolve and regulatory bodies demand...
Global Capability Centers

Unlocking the Power of Global Capability Centers (GCCs) in Biopharma: Drive Efficiency, Innovation, and Scientific Excellence

As global biopharma companies face rising demands for efficiency, standardization, and scientific excellence, Global Capability...

“Voice of Patient” in Publications: Trends and Perspectives

This page contains a poster presented at the 21st Annual Meeting of ISMPP (International Society for Medical Publication...
Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks like it may be particularly challenging...
Rare diseases

Rare Diseases – An Evolving Medical Communications Landscape

A disease is considered rare when it affects fewer than 1 in 2,000 people. However...

Learn more ABOUT our company.